R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Harbour BioMedHKG: 2142

Nona Biosciences Partners with Dr. Michael S. Diamond for Viral Disease Monoclonal Antibody Research

MerckNYSE: MRK

Merck and XtalPi Leverage Molecular Dynamics to Enhance Small-Molecule Crystallization

CRISPRGene therapy

HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency

Diapin TherapeuticsNASH

Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment

Show More